Related Experiment Video

Updated: May 30, 2026

Synthesis and Reaction Chemistry of Nanosize Monosodium Titanate
08:44

Synthesis and Reaction Chemistry of Nanosize Monosodium Titanate

Published on: February 23, 2016

Pharmaceutical formulation affects titanocene transferrin interactions

Katherine M Buettner1, Robert C Snoeberger, Victor S Batista

  • 1Yale University, New Haven, CT 06520-8107, USA.

Dalton Transactions (Cambridge, England : 2003)
|August 18, 2011
PubMed

Insights

Titanocene dichloride (TDC) derivatives like MKT4 show anticancer activity. MKT4 interacts differently with human serum transferrin than TDC, potentially impacting clinical trial outcomes.

Area of Science:

  • Inorganic Chemistry
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Titanocene dichloride (TDC) exhibits anticancer properties, leading to the development of derivatives.
  • MKT4, a stable formulation of TDC, advanced to human clinical trials (Phase I and II).
  • Human serum transferrin is a known carrier for titanium-based anticancer drugs.

Purpose of the Study:

  • To characterize MKT4 speciation and its interaction with human serum transferrin.
  • To compare the binding kinetics and thermodynamics of MKT4 versus TDC with transferrin.
  • To investigate the influence of malate on MKT4-transferrin interactions.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy ((1)H and (13)C)
  • Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry
  • UV/vis absorption and fluorescence quenching spectroscopy
  • Density Functional Theory (DFT) calculations

Main Results:

  • MKT4 exhibits distinct binding kinetics and a different molar absorptivity (7500 M(-1) cm(-1) per site) with transferrin compared to TDC.
  • Malate, present in the MKT4 buffer, acts synergistically, altering charge transfer energy and reducing molar absorptivity to 5000 M(-1) cm(-1) per site.
  • These formulation-induced differences in transferrin binding may explain clinical trial observations.

Conclusions:

  • The formulation of titanocene dichloride as MKT4 significantly alters its interaction with human serum transferrin.
  • Malate plays a crucial role in modulating MKT4-transferrin binding.
  • Understanding these formulation effects is critical for interpreting clinical trial data and developing future titanium-based anticancer agents.

More Related Videos

Study of Short Peptide Adsorption on Solution Dispersed Inorganic Nanoparticles Using Depletion Method09:43

Study of Short Peptide Adsorption on Solution Dispersed Inorganic Nanoparticles Using Depletion Method

Published on: April 11, 2020

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Related Concept Videos

Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...